SARS: epidemiology

By M. Chan-Yeung, R. Xu. Respirology (Carlton South. Print), 2003

638 citations recorded by the source corpus.

Severe acute respiratory syndrome (SARS) originated in Southern China in November 2002, and was brought to Hong Kong in February 2003. From Hong Kong, the disease spread rapidly worldwide but mostly to Asian countries. At the end of the epidemic in June, the global cumulative total was 8422 cases with 916 deaths (case fatality rate of 11%). People of all ages were affected, but predominantly females. Health care workers were at high risk and accounted for one‐fifth of all cases. Risk factors for death included old age and comorbid illnesses, especially diabetes. The disease is caused by a novel coronavirus and is transmitted by droplets or direct inoculation from contact with infected surfaces. Contaminated sewage was found to be responsible for the outbreak in a housing estate in Hong Kong affecting over 300 residents. The mean incubation period was 6.4 days (range 2–10). The duration between onset of symptoms and hospitalisation was from 3 to 5 days. The relatively prolonged incubation period allowed asymptomatic air travellers to spread the disease globally. The number of individuals infected by each case has been estimated to be 2.7. Effective control of nosocomial transmission included early detection of disease, strict isolation of patients, practice of droplet and contact precautions and compliance with the use of personal protective equipment. Effective control of disease spread in the community included tracing and quarantine of contacts. Development of a validated diagnostic test and an effective vaccine as well as elimination of possible animal reservoirs are measures needed to prevent another epidemic.

Subfields: Infectious Diseases, Modeling and Simulation, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/cb1cfedf62d45ea4b2fcbd56080e7aec83c27124

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

In Modeling and Simulation

In Pulmonary and Respiratory Medicine

Citations in the corpus

Laboratory Diagnosis of COVID-19: Current Issues and Challenges (2020, methodology): “Antibodies to the N protein are frequently detected in COVID-19 patients (67, 68), suggesting that the N protein may be one of the immunodominant antigens in the early diagnosis of COVID-19 (69).”
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease (2018, background): “Although the SARS epidemic was controlled by public health measures within a year of its emergence, the virus spread to over 30 countries and was associated with a 10% mortality rate (3).”
Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge (2008, neutral): “10% fatality rate (5, 19).”
A Review of Coronavirus Disease-2019 (COVID-19) (2020, neutral): “%) before being contained [4].”
A Comprehensive Review of the COVID-19 Pandemic and the Role of IoT, Drones, AI, Blockchain, and 5G in Managing its Impact (2020, background): “The past two decades have witnessed the emergence of several viral outbreaks with different forms of coronavirus at the helm, such as the 2002-2004 SARS-CoV outbreak [5], and the more recent middle east respiratory syndrome coronavirus (MERS-CoV) infection of 2012.”